Latest News: Treatments & Research

Registration for SMA Europe’s 2nd International Scientific & Clinical Congress on SMA Now Open

19 July 2019 / Posted in: Treatments & Research

The conference will be held at Génocentre in Evry, south of Paris between 5th & 7th February 2020 and is open for healthcare professionals and researchers in SMA to attend. The congress will feature a series of talks and workshops covering key scientific and clinical research fields in SMA.

Read full story

Response from NICE to the SMA Community re: NICE's Communications About Access to Nusinersen

10 July 2019 / Posted in: Treatments & Research

We have received this reply in response to the letter sent by SMA UK, MDUK and TreatSMA on 14th June 2019.

Read full story

NICE / NHS England announce changes to the nusinersen Managed Access Agreement

03 July 2019 / Posted in: Treatments & Research

The MAA for nusinersen (Spinraza) will now include paediatric patients who have recently (in the previous 12 months) lost the ability to walk independently. It also commits to considering any significant evidence being made available by Biogen in relation to all with SMA Type 3 who are non-ambulant, that may impact on the eligibility criteria of the MAA. These are just two changes following many confidential discussions which we have been unable to report on until now.

Read full story

Scottish Government Updates On Access To Nusinersen For Those With SMA Types 2 And 3

02 July 2019 / Posted in: Treatments & Research

Following recent communication from the Scottish Government, the Scottish Medicines Consortium webpage for nusinersen has been updated to advise that, as well as being available for those with SMA Type 1, from July 2019 nusinersen can be prescribed for those with SMA Types 2 and 3.

Read full story

Guide to the 2017 International Standards Of Care For SMA Launched Today

26 June 2019 / Posted in: Treatments & Research

The SoC is now available via the TREAT-NMD website. It describes what assessments and interventions families and adults should expect to find in any neuromuscular centre anywhere.

Read full story

Your Views on the Possible Provision of Zolgensma by NHS England, for Infants who have SMA Type 1

25 June 2019 / Posted in: Treatments & Research

Patient groups would like to find out what you think about this new treatment so that we can include your views in our submissions to the National Institute for Health and Care Excellence (NICE). Our survey closes on 21st July 2019.

Read full story

Update re Nusinersen MAA

20 June 2019 / Posted in: Treatments & Research

We are so sorry to hear of the continued heightened distress in the SMA Community caused by NICE / NHS England’s decisions and communications to date. We are doing all we can to obtain a reply to the letter sent by clinicians and the patient groups on 14th June. This was sent following consultation, advice and a joint decision that this step was the most promising way to obtain a change to the MAA.

Read full story

Patient Advocacy Groups and Clinicians write to NICE & NHSE about the nusinersen MAA and the impact this has had on the SMA Community

14 June 2019 / Posted in: Treatments & Research

Today we have co-signed two letters to address the concerns that are being widely expressed about the nusinersen Managed Access Agreement (MAA).

Read full story

Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers

11 June 2019 / Posted in: Treatments & Research

Scholar Rock announced that SRK-015 was well-tolerated in healthy volunteers across all tested doses and shows robust and durable target engagement, supporting evaluation in the Phase 2 trial in SMA, which is currently ongoing.

Read full story

NICE Announces Appraisal of the Treatment Zolgensma for Infants with SMA Type 1

10 June 2019 / Posted in: Treatments & Research

Following an application by AveXis, NICE is progressing an appraisal of this treatment to see if it will recommend it for provision by NHS England for the treatment of infants with SMA Type 1. We will be asking the Community for their views and making a submission by the deadline of 31st July.

Read full story